Electromed, Inc.
No SEC Form 4 filings for $ELMD in the last 30 days.
See all $ELMD insider activity →Electromed (ELMD) reported Q4 2026 revenue growth of 11.6% to $19.4M, with full-year revenue up 15.3% to $73.8M. Growth was driven by home care and distributor channels, while hospital revenue declined 29%. The company expanded its sales force and highlighted its SmartVest product's market potential. CEO Jim Armstrong announced his planned retirement in April 2027.
Electromed, Inc. reported 15% Q4 home care revenue growth and 29% hospital revenue decline, driven by sales and longer sales cycles. The company expects double-digit growth in 2027, with strategic investments in digital solutions and sales force expansion. CEO James Cunniff will retire in April 2027. The company aims to expand payer coverage and product lines.
Electromed, Inc. (ELMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Electromed, Inc. Announces Record Fiscal 2026 Fourth Quarter and Full Year Financial Results Strong homecare revenue growth and expanded operating leverage drive record operating income in Fiscal 2026 NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Electromed, Inc. (“Electromed
Over the past 7 days, alphai's AI scored 1 news story mentioning ELMD (Electromed, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent ELMD coverage spans financial news, earnings and insider activity.
Revenue growth and leadership transition may affect valuation and investor sentiment.
Electromed, Inc. reported 15% Q4 home care revenue growth and 29% hospital revenue decline, driven by sales and longer sales cycles. The company expects double-digit growth in 2027, with strategic investments in digital solutions and sales force expansion. CEO James Cunniff will retire in April 2027. The company aims to expand payer coverage and product lines.
Strong top‑line growth and higher margins suggest upside potential, while cash generation offsets the modest share buyback.
This is a routine insider sale with no stated 10b5-1 plan, but it does not disclose new company fundamentals.
This is a routine insider sale with no stated operational or financial catalyst, so near-term price impact is likely limited.
alphai scores every news story that mentions ELMD with an AI model for sentiment and relevance, and aggregates insider trades from Electromed, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Electromed (ELMD) reported Q4 2026 revenue growth of 11.6% to $19.4M, with full-year revenue up 15.3% to $73.8M. Growth was driven by home care and distributor channels, while hospital revenue declined 29%. The company expanded its sales force and highlighted its SmartVest product's market potential. CEO Jim Armstrong announced his planned retirement in April 2027.
3 min readElectromed, Inc. reported 15% Q4 home care revenue growth and 29% hospital revenue decline, driven by sales and longer sales cycles. The company expects double-digit growth in 2027, with strategic investments in digital solutions and sales force expansion. CEO James Cunniff will retire in April 2027. The company aims to expand payer coverage and product lines.
3 min readElectromed, Inc. (ELMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Electromed, Inc. Announces Record Fiscal 2026 Fourth Quarter and Full Year Financial Results Strong homecare revenue growth and expanded operating leverage drive record operating income in Fiscal 2026 NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Electromed, Inc. (“Electromed
2 min readCunniff James L. (CEO and President) sold 9,700 shares of Electromed, Inc. (ELMD) at an average of $36.50 ($36.25–$37.77, $0.35M total) across 3 trades on 2026-06-08.
2 min readNagel Bradley M. (Chief Financial Officer) sold 11,801 shares of Electromed, Inc. (ELMD) at an average of $36.35 ($36.34–$37.11, $0.43M total) across 2 trades on 2026-06-04.
1 min readThis article details an SEC Form 144 filing by Electromed, Inc. (ELMD) concerning a proposed sale of 40,000 shares of common stock with an aggregate market value of $1,419,357.79. The securities were acquired via an option grant on July 1, 2016, and are intended for sale on May 15, 2026, through Fidelity Brokerage Services. The filing indicates a neutral impact and sentiment.
2 min readElectromed (ELMD) could produce exceptional returns because of its solid growth attributes.
3 min readElectromed (ELMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2 min readThe consensus price target hints at a 39.2% upside potential for Electromed (ELMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2 min read
